Sign In
Buy LEGN
$29.30
-0.0400 (-0.136%)
At Close: Jun 23, 2026
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
08:02am, Thursday, 18'th Jun 2026
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday.
Legend Biotech Corporation Announces Pricing of Public Offering
09:21pm, Wednesday, 17'th Jun 2026
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing
Legend Biotech Corporation Announces Proposed Public Offering
04:29pm, Wednesday, 17'th Jun 2026
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that it has
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependen
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data f
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
08:32am, Wednesday, 03'rd Jun 2026
Legend Biotech (LEGN) remains a buy as Carvykti's earlier-line use drives superior efficacy, safety, and manufacturing success, signaling a structural shift in multiple myeloma therapy. Recent CARTITU
Dow, S&P 500 Hit Fresh Records After Market Rebound
11:53am, Tuesday, 02'nd Jun 2026
Stocks are higher midday, with the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJI) hitting record highs
Legend's experimental cell therapy shows promise in blood cancer patients
09:31am, Tuesday, 02'nd Jun 2026
Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fighting cells within patients may work for a type of blood cancer, the company said on Tuesday.
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising prelimin
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
10:00am, Monday, 01'st Jun 2026
BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced first-in-human clinic
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
07:14am, Monday, 01'st Jun 2026
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
10:03pm, Sunday, 31'st May 2026
Legend Biotech NASDAQ: LEGN used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multi
Legend Biotech Announces Presentations at ASCO 2026
05:00pm, Thursday, 21'st May 2026
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at t
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
03:36pm, Sunday, 17'th May 2026
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
09:20am, Thursday, 14'th May 2026
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
